At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
VIB4920 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
In Brief
A Phase 1 clinical trial evaluating VIB4920 and Placebo for Adult Onset Rheumatoid Arthritis. Completed, enrolled 57 participants across 12 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Onset Rheumatoid Arthritis
CountriesPoland, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedMay 2016
Primary CompletionMay 2018
Study CompletionAug 2018
TodayJul 2026
First PostedMay 23, 2016
Enrollment StartMay 12, 2016
Primary CompletionMay 21, 2018
Study CompletionAug 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.1 years ago
Interventions
VIB4920drug
Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
Placeboother
Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.